Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis

NCT06371040 · clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
9
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Ting Chang, MD